Rock Creek Pharmaceuticals Inc

Rock Creek Pharmaceuticals — Investor Presentation (July 2014)

46 slides from Rock Creek Pharmaceuticals's investor presentation, Jul 1, 2014

  1. Slide 1: Rock Creek Pharmaceuticals, Inc.

    Slide 1: Rock Creek Pharmaceuticals, Inc.

    O RockCreek June 30,2014 Pharmaceuticals, Inc.

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements Certain statements that will be made during this presentation constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements indude, but are not limited to statements identified by words such as "believes,"

  3. Slide 3: Rock Creek Pharmaceuticals Development

    Slide 3: Rock Creek Pharmaceuticals Development

    Rock Creek Pharmaceuticals Development Drug development company exploiting the anti-inflammatory and anti-addictive properties of new chemicalentities derived from naturally occurring alkaloids. « Peer-reviewed scientific foundations Continued research on efficacy and tolerability. Large Pre-IND hum

  4. Slide 4: Human Diseases of Inflammation

    Slide 4: Human Diseases of Inflammation

    Human Diseases of Inflammation XN IF Cancer Cardiovascular diseases Pulmonary disease Neurological Intl ti Inflammatory diseases WUE UTES Bowel Disease Autoimmune "4 diseases Diabetes Il Arthritis Q RockCreek

  5. Slide 5: Anatabine

    Slide 5: Anatabine

    Anatabine « Aminor alkaloid + Found in the solanaceae plant family (potato, pepper, eggplant, tomato), as well as tobacco and nightshade * A cholinergic agonist © RockCreek Pharmaceuticals, Inc.

  6. Slide 6: Anatabine Science

    Slide 6: Anatabine Science

    Anatabine Science Anatabine: Reduces inflammatory molecules (iNOS, TNF-«, Cox2, IL-1b, etc.) via reduced gene expression, thus being a potential therapy for inflammatory and immunological diseases. Anatabine Attributes: * Small Molecule + Cholinergic Receptor Activation + Excellent Bioavailability +

  7. Slide 7: Comparison of chemical structures of Anatabine and Nicotine

    Slide 7: Comparison of chemical structures of Anatabine and Nicotine

    Comparison of chemical structures of Anatabine and Nicotine (S)-3-(1-Methyl-2-pyrrolidinyl) pyridine YX a" (-)-Nicotine i) N | \ Pe CH N —. H \ (S)-1,2,3,6-Tetrahydro-2,3'-bipyridine \ yj (-)-Anatabine HN Anatabine Nicotine © RockCreek Pharmaceuticals, Inc.

  8. Slide 8: Comparison: Nicotine to Anatabine

    Slide 8: Comparison: Nicotine to Anatabine

    Comparison: Nicotine to Anatabine H S cy‘. CY% Sy CH Sy | H Nicotine Anatabine Nicotine, exerts anti-inflammatory effects in multiple cell types and has been shown to benefit various disorders in which inflammation is implicated. Nicotine has a short half life, is toxic (high doses) and most importa

  9. Slide 9

    Slide 9

  10. Slide 10: Pentameric Acetylcholine Receptor

    Slide 10: Pentameric Acetylcholine Receptor

    Pentameric Acetylcholine Receptor Pentamer nAChR top view (extracellular Pentamer nAChR side view domain) DE (Rock Creek Pharmaceuticals, Inc. 10

  11. Slide 11: ElectroStatic Ribbon Model

    Slide 11: ElectroStatic Ribbon Model

    ElectroStatic Ribbon Model Acetylcholine Binding at the interface of Anatabine Binding at the interface of a7- a7-nAChR nAChR © RockCreek Pharmaceuticals, Inc.

  12. Slide 12: Acetylcholine Receptor Activation

    Slide 12: Acetylcholine Receptor Activation

    Acetylcholine Receptor Activation Extracellular Py wy ey Intracellular ge Acetylcholine ., Cellular function Sodium ion

  13. Slide 13: Nuclear Factor Kappa B (NF-KB)

    Slide 13: Nuclear Factor Kappa B (NF-KB)

    Nuclear Factor Kappa B (NF-KB) NF-kB is a protein complex that controls the transcription of DNA. NF-kB is found in almost all animal cell types and is involved in cellular responses to external stimuli. NF-kB plays a key role in regulating cellular response to inflammation. Specifically, NF-kB cont

  14. Slide 14: NF-kb Signaling pathways

    Slide 14: NF-kb Signaling pathways

    NF-kb Signaling pathways:

  15. Slide 15: Functional Receptor Binding Summary

    Slide 15: Functional Receptor Binding Summary

    Functional Receptor Binding Summary nACh Anatabine Potency Function Channel Activity relative to Nicotine a4B2 Full Agonist <<less Addiction (200-fold) a3B4 Partial Agonist < less ? a7 Full Agonist ~ Anti- inflammatory DN () Rock Creek 15 Pharmaceuticals, Inc.

  16. Slide 16: Anatabine: Widespread Anti-inflammatory Properties in pre-clinical models

    Slide 16: Anatabine: Widespread Anti-inflammatory Properties in pre-clinical models

    Anatabine: Widespread Anti-inflammatory Properties in pre-clinical models Suppresses brain inflammation and A-Beta accumulation in animal models of Alzheimer's proves motor n of the spinal cord in animal

  17. Slide 17: Peer Reviewed Published Studies

    Slide 17: Peer Reviewed Published Studies

    Peer Reviewed Published Studies Anatabine Lowers Alzheimer’s AB Production in vitro and in vivo + Publication: European Journal of Pharmacology, Sept 2011 + This peer-reviewed article explores the in vitro and in vivo activity of anatabine in Alzheimer's disease. It states that anatabine lowers Alzh

  18. Slide 18: Anatabine dose dependently lowers NF-kB activity in vivo

    Slide 18: Anatabine dose dependently lowers NF-kB activity in vivo

    in vivo (OINL JO 9%) aSB1AJIIN] G44N Anatabine dose dependently lowers NF-kB activity (Control, TNFa and TNFa + Anatabine) 120 90 60 30 0 a CR 18

  19. Slide 19: Effects of Anatabine on Acute Brain Inflammation

    Slide 19: Effects of Anatabine on Acute Brain Inflammation

    Effects of Anatabine on Acute Brain Inflammation Study Design: Water or TNF- OL Anatabine ip intracranial injection injection NF-KB activation

  20. Slide 20: Anatabine Inhibits Brain NF-KB Activation

    Slide 20: Anatabine Inhibits Brain NF-KB Activation

    Anatabine Inhibits Brain NF«KB Activation a2) © > 2 a ~ uw Zz

  21. Slide 21: Experimental Autoimmune Encephalomyelitis

    Slide 21: Experimental Autoimmune Encephalomyelitis

    Experimental Autoimmune Encephalomyelitis On day 1, 10 Week-old,C57B16/J Female mice were immunized with 300 ug of murine MOG35-55 (myelin oligodendrocyte glycoprotein). Mice were immediately and at 48 hrs injected IP with 300ug of Pertussis toxin. Mice were randomized in a placebo group (n=15) rece

  22. Slide 22: Incidence of hind limb paralysis in Placebo or Anatabine treated EAE mice

    Slide 22: Incidence of hind limb paralysis in Placebo or Anatabine treated EAE mice

    Incidence of hind limb paralysis in Placebo or Anatabine treated EAE mice 70 v a o 2 & 52.5 2 E a a ‘® Placebo (n=15) = 35 @® Anatabine (n=15) S vo 8 § 17.5 a=} iv] £ 0 0 2 4 6 8 10 12 14 16 18 Day After MOG Vaccination DE () Rock Creek 22 Pharmaceuticals, Ino.

  23. Slide 23: Control EAE Placebo EAE Anatabine

    Slide 23: Control EAE Placebo EAE Anatabine

    Control EAE Placebo EAE Anatabine Reduced nerve damage in Anatabine treated EAE mouse =a Spinal Cord cS = o z Fi a o 3 a g 5 a & g $ q Control (n=6) EAE Placebo (n=15) _ EAE Anatabine (n=14)

  24. Slide 24: Anatabine inhibits Inflammatory Cytokines in Blood of EAE mice

    Slide 24: Anatabine inhibits Inflammatory Cytokines in Blood of EAE mice

    Anatabine inhibits Inflammatory Cytokines in 400 300 xe) 2 5 c ° 1s) . fo} & G 200 ‘= x [o} 2 > U — =] 2 wo nn Blood of EAE mice i Control I EAE Placebo 0) EAE Anatabine

  25. Slide 25: Normalization of Inflammatory Spleen Cytokines in EAE mice by Anatabine

    Slide 25: Normalization of Inflammatory Spleen Cytokines in EAE mice by Anatabine

    Spleen Cytokine (% of control) Normalization of Inflammatory Spleen Cytokines in EAE mice by Anatabine 500 375 i Control 250 Il EAE Placebo EAE RCP006 125 0 IFNy IL-18 - TNF-a

  26. Slide 26: Proposed Common Mechanism(s) of Action of Anatabine

    Slide 26: Proposed Common Mechanism(s) of Action of Anatabine

    Proposed. Common Mechanism(s) of Action of Anatabine across different CNS (and non-CNS) conditions Activation of alpha 7 nAchR on microglia (macrophage, monocytes, B-cells, T-cells) v Suppression of inflammatory activity (via & NF-kB) reduced brain reduced inflammatory reduced tissue cytokine releas

  27. Slide 27: Safety Profile

    Slide 27: Safety Profile

    Safety Profile Preclinical safety, toxicity, genotoxicity, teratogenicity evaluations. © 90 Day repeat-dose toxicity, rat studies Early, Multiple Human Studies (> 800 dosed w/ anatabine formulations) + Tobacco Craving/Nicotine withdrawal « Hashimoto's Thyroiditis « Inflammatory Markers, C-Reactive P

  28. Slide 28: Human studies

    Slide 28: Human studies

    Human studies Pharmacokinetics «Safety, Tolerability Nicotine Craving «Alzheimer's Disease Hashimoto's Thyroiditis C-reactive protein eInternet-based joint pain questionnaire

  29. Slide 29: Auto-Immune Thyroiditis Human Trial

    Slide 29: Auto-Immune Thyroiditis Human Trial

    Auto-Immune Thyroiditis Human Trial » Evaluating the Dietary Supplement, Anatabloc, in Human Thyroid Health, * Primary Outcome: Safety and Tolerability * Secondary Outcome: Anti-thyroid auto- antibodies, thyroid structure, and thyroid function » Enrollment 165 people: 5-visits, 12-week, double- blin

  30. Slide 30: Published Human Results

    Slide 30: Published Human Results

    Published Human Results Journal for Clinical Endocrinology and Metabolism, Oct 31, 2013 ’Anatabine supplementation decreases thyroglobulin antibodies in patients with chronic lymphocytic autoimmune (Hashimoto's) thyroiditis: A randomized controlled clinical trial” (Schmeltz, Blevins, Aronoff, Ozer,

  31. Slide 31: Thyroglobulin antibodies

    Slide 31: Thyroglobulin antibodies

    31 Thyroglobulin antibodies (absolute change over baseline) Reduced Anti-thyroglobulin antibodies in Anatabine treated Thyroiditis patients 20 0 -20 40 -60 p= 0.027 4 Weeks of tre: 8 12 ‘atment % of patients with >20% decrease in TgAb g 80 60 oO HH Placebo 1 Anatabine p= 0.028 p=06ss P= OS1S + 8 12

  32. Slide 32: Joint pain questionnaire of Anatabine dietary supplement users

    Slide 32: Joint pain questionnaire of Anatabine dietary supplement users

    Joint pain questionnaire of Anatabine dietary supplement users 706 invitees (ordering monthly Anatabloc:) 282 (40%) respondents (selection bias) v 232 (82%) claiming benefit for joint pain Male, Caucasian, ~60 yrs Knees, Shoulder, Back, Wrists/Hands/Fingers 50% > 7yrs duration Clinical Medicine Insi

  33. Slide 33: Anatabine Summary

    Slide 33: Anatabine Summary

    Anatabine Summary + Pharmacologically active alkaloid * Cholinergic agonist at therapeutically relevant receptors + Preclinical data consistent with anti-inflammatory activity + "Clinical" data with dietary supplement suggests beneficial effects in joint pain and auto-immune thyroiditis + Well toler

  34. Slide 34: Potential Clinical targets for Anatabine

    Slide 34: Potential Clinical targets for Anatabine

    Potential Clinical targets for Anatabine (and related compounds) e Arthritic Conditions (Osteoarthritic Pain) e Inflammatory Bowel Disorders _—_ (Ulcerative Colitis) e Auto-immune disorders (Thyroiditis) e CNS (Alzheimer’s Disease) (Multiple Sclerosis) (Nicotine Addiction) e Dermatology (Psoriasis)

  35. Slide 35: Pipeline

    Slide 35: Pipeline

    Pipeline Completed extensive in vitro and.in vivo toxicological and pharmacological research on our lead drug candidate. Poised to begin our first Phase 1 Clinical trials in 2014. Candidate Chart Discovery Pre-Clinical Phase? Phase2 Phase hiatal OSTEOARTHAITIS ICLERATIVE COLITIS Pharmaceuticals, Inc

  36. Slide 36: Intellectual Property

    Slide 36: Intellectual Property

    Intellectual Property e Issued US patents: Anatabine Citrate - Novel Compound - US Patent: 8,577,999 (Oct 2013) Anatabine: Method of Synthesis - US Patent: 8207346 (June 2012) Anatabine/Yerbe Mate: Use Patent for Weight Loss and Tobacco Craving - US Patent: 8241680 (Aug 2012) ¢ Pending foreign paten

  37. Slide 37: Anti-Inflammatory Market Opportunity

    Slide 37: Anti-Inflammatory Market Opportunity

    37 ANTI-INFLAMMATORY MARKET OPPORTUNITY + U.S. non steroidal anti-inflammatory market is approximately $15 Billion « Rheumatoid Arthritis market is approximately $8 Billion Global Osteoarthritis (OA) therapeutics market is expected to grow at a rate of 8.7% annually for the next seven years to reach

  38. Slide 38: Financials

    Slide 38: Financials

    Financials Rock Creek Pharmaceuticals, Inc. (Formerly Star Scientific, Inc. ) ‘Three Months Ended March 31, 2014 2013 (Unaudited) (Unaudited) Net sales s 1123 $ 2,507 Less: Product cost of goods sold 457 1,385 Gross profit 666 1,122 Operating expenses: Sales and marketing 825 3,149 General and admin

  39. Slide 39: Financials

    Slide 39: Financials

    Financials The company reported net sales of $1.1 million for the quarter ended March 31, 2014, compared with $2.5 million forthe same period in 2013. (Sales were entirely from nutritional supplement, with the 56% decrease attributable to reduced marketing expenditures resulting in decreased sales v

  40. Slide 40: March 2014 Financing

    Slide 40: March 2014 Financing

    March 2014 Financing + Financing Package Sale of common stock for $5.1 million Warrant exercise for $4.2 million $5.8 Million credit facility * Use of Funding Po, et Support the IND/CTA applications "™—<\— : ag Phase 1 clinical trials wy Support corporate transition plan Pharmaceuticals, Inc. Ds ()

  41. Slide 41: Management

    Slide 41: Management

    Management * Dr. Michael! Mullan, MD, Phd., Chairman and Chief Executive Officer Recognized authority on Alzheimer's disease and related disorders. Trained as a physician. Medical degree and PhD in molecular genetics, from London University Inventor on the patents covering the first genetic mutation

  42. Slide 42: Board of Directors

    Slide 42: Board of Directors

    Board of Directors Benjamin M. Dent: CEO of the Dent Consulting Group LLC and an adjunct professor with the St. Louis University graduate program in Entrepreneurial Management. + Mr. Dent previously has served in senior financial management positions with several public and private companies, and al

  43. Slide 43: Risk Factors

    Slide 43: Risk Factors

    Risk Factors ¢ Challenge of intellectual property rights and/or not obtaining additional rights. « FDA regulatory risk and oversight. Clinical studies do not reach desired endpoints. . Legal challenges regarding corporate governance. . Ongoing operating losses, access to cash, sustainable funding an

  44. Slide 44: Projected Milestones

    Slide 44: Projected Milestones

    Projected Milestones ast Otr 2015: Phase Two Efficacy Studies Begin 3rd/4th Otr 2014: Phase One Safety, PK, etc. Healthy Volunteers 2nd Otr 2014: ty, PK, Y Preparation and Filing of US IND

  45. Slide 45: Strategic Summary

    Slide 45: Strategic Summary

    Strategic Summary: ¢IND - Filed, under FDA review * Target disease evaluation - Under review * Clinical site evaluation for Phase 1- Identified * Corporate Transition - Substantially Completed Pharmaceuticals, Inc. DI (Rock Creek 45

  46. Slide 46: Rock Creek Pharmaceuticals, Inc.

    Slide 46: Rock Creek Pharmaceuticals, Inc.

    © RockCreek — Pharmaceuticals, Inc. June 30, 2014

Source: SEC EDGAR · 8-K filed Jul 1, 2014

More decks from Rock Creek Pharmaceuticals Inc